Uracil/tegafur plus oral calcium folinate in advanced breast cancer

Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Richardet, Eduardo Arnoldo, Pedraza, Cecilia, Mickiewicz, Elizabeth, Lerzo, Guillermo, Bonamasa, Miguel, Coppola, Federico, Elli, Alicia, Uranga, Graciela, Jovtis, Silvia, Bruno, Mario, Ventriglia, Mónica, Cuevas, María Andrea
Formato: Artículo
Lenguaje:Español
Publicado: 1999
Materias:
R Medicina (General)
Acceso en línea:http://pa.bibdigital.ucc.edu.ar/3734/1/A_Richardet_Pedraza_Mickiewicz_Bonamasa_Coppola_Elli_Uranga_Jovtis_Bruno_Ventriglia_Cuevas.pdf
Aporte de:
Producción Académica Universidad Católica de Córdoba (UCCor) de Universidad Católica de Córdoba
Descripción
Sumario:Uracil and tegafur (in a molar ratio of 4:1 [UFT]) has proven activity against breast cancer and is delivered in an easy-to-administer oral formulation. Orzel, which combines UFT with the oral biomodulator, calcium folinate, may provide even greater antitumor efficacy against breast cancer. Here, we describe the preliminary results of this phase H trial investigating the feasibility of 250 mg/m2/day of UFT plus 45 mg/day of oral calcium folinate administered to highly pretreated patients with advanced breast cancer. The results indicate a highly tolerable regimen and an overall response rate of 27.8% in a group of poor-prognosis patients. These findings warrant continued investigation.

Ejemplares similares